Skip to content
Film Television Auditions – Lifestyle
Author:
Newron Pharmaceuticals SpA
Newron announces completion of screening for enrollment in pivotal Phase 3 ENIGMA-TRS 1 study with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
September 2, 2026